Characterizing advanced breast cancer heterogeneity and treatment resistance through serial biopsies and comprehensive analytics.

ABSTRACT: Molecular heterogeneity in metastatic breast cancer presents multiple clinical challenges in accurately characterizing and treating the disease. Current diagnostic approaches offer limited ability to assess heterogeneity that exists among multiple metastatic lesions throughout the treatment course. We developed a precision oncology platform that combines serial biopsies, multi-omic analysis, longitudinal patient monitoring, and molecular tumor boards, with the goal of improving cancer management through enhanced understanding of the entire cancer ecosystem within each patient. We describe this integrative approach using comprehensive analytics generated from serial-biopsied lesions in a metastatic breast cancer patient. The serial biopsies identified remarkable heterogeneity among metastat

SUBMITTER: Li A 

PROVIDER: S-EPMC7997873 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature